Cybin to host cyb003 topline depression study review and r&d briefing on november 30, 2023, in new york city

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that it will discuss its topline phase 2 safety and efficacy data for cyb003, its deuterated psilocybin analog being developed for the treatment of major depressive disorder, as part of an r&d investor briefing featuring a.
CYBN Ratings Summary
CYBN Quant Ranking